Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. 1986

C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin

Eighteen patients with chronic progressive multiple sclerosis (MS) were treated in an open preliminary trial of the interferon inducer and immune modulator, poly ICLC. All patients produced substantial interferon levels and experienced acute side effects, including fever and transient worsening of neurologic symptoms. Of nine patients with rapid neurologic deterioration at the time of entry into the study, only three had disease progression during treatment. We conclude that poly ICLC can be administered safely to MS patients, and that a controlled trial will be necessary to determine efficacy.

UI MeSH Term Description Entries
D007369 Interferon Inducers Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. Inducers, Interferon
D008297 Male Males
D008747 Methylcellulose Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative. BFL,Celevac,Cellothyl,Cellulone,Citrucel,Cologel,Dacryolarmes,Methocel,Methyl Cellulose,Muciplasma,Cellulose, Methyl
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D011070 Poly I-C Interferon inducer consisting of a synthetic, mismatched double-stranded RNA. The polymer is made of one strand each of polyinosinic acid and polycytidylic acid. Poly(I-C),Poly(rI).Poly(rC),Polyinosinic-Polycytidylic Acid,Polyinosinic-Polycytidylic Acid (High MW),Polyriboinosinic-Polyribocytidylic Acid,Polyribose Inosin-Cytidil,Inosin-Cytidil, Polyribose,Poly I C,Polyinosinic Polycytidylic Acid,Polyriboinosinic Polyribocytidylic Acid,Polyribose Inosin Cytidil
D011107 Polylysine A peptide which is a homopolymer of lysine. Epsilon-Polylysine,Poly-(Alpha-L-Lysine),Epsilon Polylysine
D002266 Carboxymethylcellulose Sodium A cellulose derivative which is a beta-(1,4)-D-glucopyranose polymer. It is used as a bulk laxative and as an emulsifier and thickener in cosmetics and pharmaceuticals and as a stabilizer for reagents. Carboxymethyl Cellulose,Carboxymethylcellulose,Aquacel,Aquaplast,Carmellose Sodium,Cellolax,Cethylose,Croscarmellose Sodium,Polycell,Ruspol,Sodium Carboxymethylcellulose,Carboxymethylcellulose, Sodium,Cellulose, Carboxymethyl,Sodium, Carboxymethylcellulose,Sodium, Carmellose,Sodium, Croscarmellose
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
November 1983, Annals of neurology,
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
August 1987, Archives of neurology,
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
June 2000, Cellular and molecular biology (Noisy-le-Grand, France),
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
January 1984, Annals of the New York Academy of Sciences,
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
April 1995, Der Nervenarzt,
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
January 1987, NITA,
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
January 1989, Advances in experimental medicine and biology,
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
October 2017, Multiple sclerosis (Houndmills, Basingstoke, England),
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
October 2017, Multiple sclerosis (Houndmills, Basingstoke, England),
C T Bever, and A M Salazar, and E Neely, and B E Ferraraccio, and J W Rose, and H F McFarland, and H B Levy, and D E McFarlin
August 1995, Der Nervenarzt,
Copied contents to your clipboard!